Plateforme digitale intégrée et collaborative à destination des patients diabétiques insulino-requérants, de leurs aidants et de leurs professionnels de santé.

With 51% of physicians reporting that prior authorizations (PAs) for prescribed branded and specialty medications have significantly expanded over the last five years, PA requirements continue to be a major hurdle for patients and healthcare providers (HCPs) alike.

There are several factors to consider when determining if insulin is the right treatment option for a patient with type 2 diabetes. And once a patient is prescribed insulin therapy, it’s just as important to consider the factors that might lead to nonadherence. That’s why Dr. Charles Turck speaks with Dr. Javier Morales about those factors and how we can improve our patients’ adherence to their insulin regimens.

Obesity is a disease, and America’s healthcare providers and hospital systems must be part of changing how we treat it. That means many of us in the health ecosystem must reexamine how we view patients with excess weight.

The researchers saw that the risk of developing diabetes rose as COVID-19 severity increased. When compared to people who did not have COVID-19 and were not hospitalized or admitted to intensive care, those who were hospitalized or admitted to intensive care had roughly four times the risk.

The second quarter of 2022 kicked off with a new life sciences company joining the public markets, but not via an IPO or merger. Becton Dickinson on Friday completed the spinoff of its diabetes care business, Embecta, which now trades on the Nasdaq.

Whether people with diabetes prefer face-to-face, telephone or video consultations depends on whom you ask. We summarise the findings of two published online surveys and report the results of our own paper survey, distributed through the Diabetes Research & Wellness Foundation monthly newsletter, Diabetes Wellness News. Respondents to the online surveys were positive about the benefits of virtual consultations, although there were concerns about confidentiality, safeguarding and identification of emotional issues.

Diabetes-focused life sciences company Zucara Therapeutics released preclinical findings on a daily therapy to slow and prevent plummeting blood glucose levels in Type 1 diabetes patients. The results were published in the peer-reviewed journal, Diabetes, Obesity and Metabolism. Dubbed ZT-01, it could in theory restore the body's ability to release glucagon, an essential component of blood glucose level regulation.

The Diabetes Self-Management Program (DSMP) is a six-week group program for people with type 2 diabetes and is designed to help participants manage their diabetes symptoms including tiredness, pain, and emotional issues by helping them learn skills to better manage their diabetes day-to-day like action planning, problem-solving and decision making. This program is also beneficial for caregivers and are encouraged to enroll. DSMP is an evidence-based program developed at Stanford University and now managed by the Self-Management Resource Center. Participants will receive a free Living a Healthy Life with Chronic Conditions book and a relaxation CD/MP3 for enrolling.

We propose a prototype for a dashboard summary report of glucose, insulin, meals, and activity data intended for providers and patients on MDI using connected pens and CGM. Our goal is to stimulate development of a standardized approach.

A new treatment using stem cells that produce insulin has surprised experts and given them hope for the 1.5 million Americans living with the disease.

The randomized study recruited 175 adults who were taking a longer-acting basal insulin, meaning they would only take it once or twice per day. Those who used a CGM for eight months saw their hemoglobin A1C levels decrease from 9.1% to 8%.

Researchers create new five-module CAR-T cell that shows potential against Type 1 diabetes. The 5MCar cells were tested in a study in experimental T1D mouse models. When the biomimetic cells were adoptively transferred to the mice, the manifestation of T1D was prevented due to targeting of autoimmune CD4+ T cells. The results of the study show that T cells that express 5MCar can effectively destroy pathogenic autoimmune T cells and prevent the development of T1D. Also, the biomimetic design enhances sensitivity and may improve the toxicity profile seen with convention CAR-T designs. Further studies can determine if this approach is a safe and effective immunotherapy for humans with T1D and other aberrant T-cell–induced disorders.

Gut bacteria may act on the gut-brain axis to alter appetite control and brain function as part of the genesis of eating disorders. The gut-brain axis, connected via neural, hormonal, and immunological pathways, is a bi-directional communication system that is initially recognized for its role in regulating digestive function and food intake.

The study met both primary endpoints with Soliqua demonstrating noninferiority of blood sugar (HbA1c) reduction and superiority on body weight change from baseline compared to premixed insulin. The study also met its key secondary endpoints with Soliqua achieving a greater proportion of people reaching a HbA1c target of <7% without weight gain, a greater proportion of people reaching a HbA1c target of <7% without weight gain and without hypoglycemia, and superiority in reduction of HbA1c compared with those using premixed insulin.

Not only do people with depression have a higher risk of developing type 2 diabetes, people with type 2 diabetes are more likely to develop depression after diagnosis.

Unfortunately, while the A1c differences between the two groups were significantly different at 6, 9, and 12 months after diagnosis, the average A1c level was still at or above 7%, for a considerable proportion of learn about participants. These results underscore the value of CGM use in improving diabetes management in young people, but also demonstrate the require for more effective management strategies in this group.

Walmart has announced a new private brand of analog insulin, the first of its kind, designed to overcome common impediments, like affordability of and access to diabetes care, especially for those without health insurance, according to a Tuesday press release shared on the company's official website. The new plan went into effect this week, and includes FexPen, which goes for $85.88, and analog insulin vials, sold at $72.88. Both products are only available through Walmart's proprietary ReliOn brand, and could save customers up to $101 per vial or $251 per package of FlexPens — a savings of 58% to 75% — read the press release.

It’s stretchable, like a band-aid, waterproof, and long lasting. In today’s Medical Moment, how this small patch may soon take the place of invasive health monitors. For many diabetics, daily monitoring of blood sugar means a finger prick. But what if there was a better way?

Unlike other companies with app-based coaching programs for managing diabetes, such as Livongo and Omada, Virta’s is based on restricting carbohydrates. Users are sent equipment, such as a connected scale, blood glucose and ketone testing strips, and enter their weight and blood sugar data.